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Introduction: Juvenile idiopathic arthritis (JIA) is a frequent childhood rheumatic disease characterized by chronic
inflammation. The latter has been related to impairment of arterial functional-structural properties, atherogenesis
and later cardiovascular events. The objective of this study was to examine intima-media thickness (IMT) and the
parameters of arterial stiffness in children with JIA at diagnosis and their correlation with JIA subtype and markers
of inflammation and atherosclerosis.
Methods: Thirty-nine newly diagnosed patients with JIA (26 girls; mean age, 13.2 ± 2.6 years) and 27 healthy
controls (9 girls; mean age, 13.6 ± 3.4 years) were included in the study. Twelve patients had oligoarthritis, fifteen
had extended oligoarthritis and twelve had rheumatoid factor–negative polyarthritis. IMT of the common carotid
artery was determined by ultrasonography, carotid-femoral pulse wave velocity (cfPWV) and augmentation index
adjusted to a heart rate of 75 beats/min (AIx@75) were determined by applanation tonometry. The serum levels of
atherosclerosis-related biomarkers, such as asymmetric dimethylarginine (ADMA), myeloperoxidase (MPO) and
adiponectin, were measured by enzyme-linked immunosorbent assay.
Results: Mean IMT (0.46 ± 0.04 vs. 0.42 ± 0.04 mm; p = 0.0003) and MPO concentration (115.2 [95 % confidence
interval {95 % CI}, 97.4–136.3] vs. 57.6 [95 % CI, 47.1–70.3] ng/ml; p < 0.0001) were higher in the patients with JIA
than in the control subjects. The cfPWV, AIx@75 and serum ADMA and adiponectin levels did not significantly differ
between the groups and JIA subtypes. Serum adiponectin level correlated negatively with AIx@75 in patients with
JIA (r = −0.38; p < 0.05).
Conclusions: Patients with JIA have increased mean IMT and elevated MPO levels at early stages of the disease.
AIx@75 was inversely independently associated with adiponectin level in the patients, suggesting that lower
adiponectin levels might influence arterial subclinical stiffening in patients with newly diagnosed JIA.Introduction
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood, with an onset
before the age of 16 years and a potential to persist into
adulthood. JIA is a heterogeneous group of disorders
with different disease progression and prognosis. Of the
JIA subtypes, persistent oligoarthritis and monocyclic sys-
temic arthritis have the best prognosis and polyarthritis* Correspondence: jaanika.ilisson@kliinikum.ee
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still have active disease and need for disease-modifying an-
tirheumatic medications in adulthood [3–5].
Many patients with active JIA may not present with high
levels of classical inflammatory markers such as C-reactive
protein or erythrocyte sedimentation rate. Therefore, stud-
ies on the role of new markers (e.g., myeloperoxidase
[MPO], asymmetric dimethylarginine [ADMA], adiponec-
tin) may open some new aspects to describe inflammation
in patients with JIA. MPO, ADMA and adiponectin have
been linked to inflammation and/or oxidative stress [6–8].
Previous studies have shown that MPO levels are higher in
patients with JIA compared with control groups [9].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tients with JIA.
Atherosclerosis is considered an inflammatory disorder
starting in childhood. Chronic inflammation has been
suggested to play an important role in the developing of
early atherosclerosis, which contributes to the develop-
ment of cardiovascular disease (CVD) [10, 11].
CVD is more frequent in patients with rheumatoid
arthritis (RA), and they are diagnosed at an earlier
age than other patients with CVD. Mortality among
RA patients is also higher than general population
and is mostly due to cardiovascular diseases [12–14].
In addition to traditional risk factors for CVD, patients
with a chronic inflammatory disease also have many
disease-specific and drug-related risk factors [13]. Recent
studies have shown that patients with RA have increased
aortic stiffness, and this is correlated with markers of in-
flammation and aortic inflammation without any clinical
signs of CVD [15, 16].
As JIA is a chronic inflammatory disease, it has long-
term effects on many organ systems, including the car-
diovascular system. Accordingly, it has been shown that
patients with JIA have a moderate risk for premature
cardiovascular events [17].
To date, only a few studies of vascular function, struc-
tural and atherosclerosis-related biomarkers in patients
with JIA have been done. They have shown impaired
endothelial dysfunction and alterations in vascular func-
tion compared with controls during the course of the
disease [18, 19]. Satija et al. reported altered arterial wall
indices in newly diagnosed patients with JIA, indicating
increased arterial stiffness [20].
The aim of the present study was to evaluate intima-
media thickness (IMT) and the parameters of arterial
stiffness in patients with JIA at the time of diagnosis and
to assess their correlation with JIA subtype and serum
markers of inflammation and atherosclerosis.
Methods
Patients and controls
This cross-sectional study included 39 children with JIA
(26 girls; mean age, 13.2 ± 2.6 years) who were patients
of the paediatric rheumatologist at the outpatient chil-
dren’s clinic of Tartu University Hospital, Estonia, and
27 healthy control subjects (9 girls; mean age, 13.6 ±
3.4 years) recruited from a previous diabetes study [21].
The study group included children aged 7–18 years with
newly diagnosed JIA (onset of symptoms before the 16th
birthday). JIA was diagnosed according to the Inter-
national League of Associations for Rheumatology cri-
teria [22]. Twenty-seven patients had oligoarthritis
(fifteen of them had extended oligoarthritis), and twelve
had rheumatoid factor (RF)-negative polyarthritis. All
patients were RF-negative, three were antinuclearantibody–positive and five were human leukocyte anti-
gen B27–positive.
Healthy control subjects were defined as without
known chronical illness at the time of enrolment, with-
out acute infection and no history of using antihyperten-
sive or lipid-lowering medications. They were matched
with the patients by age (±2 years). Three of the subjects
from the original control group were excluded because
of greater age difference. Written informed consent was
obtained from each participant and the parent or legal
representative. The study was approved by the ethics
committee of Tartu University.
Clinical and laboratory investigations
A full joint examination was performed by the same
paediatric rheumatologist during the outpatient visit.
Blood samples were obtained for nine different
biochemical markers: glucose, creatinine, total choles-
terol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol, triglycerides,
ADMA, adiponectin and MPO. The first six markers
are regularly used in clinical practice and were ana-
lysed in the local clinical laboratory using certified
standard assays. For the last three markers, serum and
plasma were stored at −80 °C until analysis. Serum
ADMA concentration was determined by using a vali-
dated enzyme-linked immunosorbent assay (ELISA) kit
(DLD Gesellschaft für Diagnostika und medizinische
Geräte mbH, Hamburg, Germany). Serum adiponectin
concentration was determined using the Human Adipo-
nectin/Acrp30 Quantikine ELISA kit (R&D Systems
Europe, Abingdon, UK). The adiponectin intraassay coeffi-
cient of variation (CV) is 4.6 %, and the interassay CV is
7.9 %. MPO was determined in serum of patients with JIA
using an enzyme immunoassay test kit (catalogue number
BC-1129; BioCheck, Foster City, CA, USA) and in plasma
of controls using an ELISA kit (BIOXYTECH enzyme im-
munoassay for MPO, catalogue number 21013; OXIS
Health Products, Portland, OR, USA), according to the
manufacturer’s instructions. MPO intraassay CV is 5.7 %
and inter-assay CV 8.5 %.
Haemodynamic measurements
Brachial blood pressure (BP) and heart rate were
recorded from the left arm with the subject in the supine
position. BP was measured with an automated digital
oscillometric BP monitor (OMRON M4-I; Omron
Healthcare Europe, Hoofddorp, the Netherlands). Ra-
dial arterial pressure waveforms were obtained with a
high-fidelity applanation tonometer (SPT-301B; Millar,
Houston, TX, USA) applied to the wrist of the left
hand. Pulse wave analysis (SCOR-Px 7.0; AtCor Med-
ical, West Ryde, Australia) was then performed to
generate a corresponding central (ascending aortic)
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has been prospectively validated for assessment of as-
cending aortic BP [23]. Augmentation index (AIx),
mean arterial pressure (MAP), central systolic blood
pressure, central diastolic blood pressure and central
pulse pressure were determined by pulse wave ana-
lysis. The AIx was calculated as the difference be-
tween the second and the first systolic peaks, divided
by pulse pressure and expressed in percentages [24].
The AIx values were adjusted to a heart rate of 75 beats/
min (AIx@75) using a built-in algorithm in the Sphygmo-
Cor Px system (AtCor Medical). The within- and
between-observer CVs for AIx@75 were 3.4 % and 7.1 %,
respectively. Pulse wave velocity was measured by the
foot-to-foot method using the same device. The aortic
pulse wave velocity (aPWV) was determined by sequen-
tially recording electrocardiogram-gated carotid and fem-
oral artery waveforms, as described in detail previously
[24]. The within- and between-observer CVs for aPWV
were 2.3 % and 6.2 %, respectively. All measurements were
made in duplicate by two trained investigators, and the
mean values were used in subsequent analysis.Assessment of carotid intima-media thickness
Carotid ultrasound for evaluation of IMT was performed
using the SonoSite M-Turbo portable ultrasound device
(SonoSite, Bothell, WA, USA) coupled to a 5- to 10-MHz
multifrequency high-resolution linear transducer. Sono-
Calc software (SonoSite) was used for calculation of mean
IMT values. The measurements were obtained with the
subject lying down, with the head extended and slightly
turned opposite to the examined carotid. Measurements
were made of the common carotid artery after the exam-
ination of a longitudinal section of 10 mm at a distance of
1 cm from the bifurcation. The measurements were per-
formed in the far wall in the lateral, anterior and posterior
projections. The within- and between-observer CVs for
mean IMT were 2.2 % and 5.9 %, respectively.
A standard deviation score (SDS) of IMT for each sub-
ject was calculated using height-specific IMT normative
values published by Jourdan et al. [25].Statistical analysis
Differences between the JIA and control groups were
studied with analysis of variance, adjusted by sex. Be-
cause the distributions of some variables were not nor-
mally distributed, they were log-transformed for analysis
as required to improve normality. The normally distrib-
uted data are presented as mean ± standard deviation;
the non-normally distributed data are presented as the
geometric mean with the 95 % confidence interval (CI).
Multiple regression analysis was performed to investi-
gate the independent determinants of AIx@75. Toexamine the associations between the variables, Pear-
son’s correlation test was used.
We used AIx@75 as a base for power calculations for t
tests. A total of 66 persons were targeted to enter this
two-group study. The probability is 80 % that the study
will detect an effect size (the smallest difference between
the means) at a two-sided 0.05 significance level if the
true difference between groups is 4.953 U. This is based
on the assumption that the standard deviation of the
response variable is 10 [26]. Differences were consid-
ered statistically different if the p value was less than
0.05. Statistical analysis was performed using the SAS
version 9.2 statistical software package (SAS Institute,
Cary, NC, USA).
Results
The subjects’ clinical and laboratory characteristics, as
well as the arterial functional-structural properties of the
study groups, are presented in Table 1.
The total cholesterol, LDL cholesterol, HDL choles-
terol and triglyceride levels did not differ between
groups. The same was found for serum ADMA and adi-
ponectin levels (Table 1).
The serum level of MPO was significantly higher in pa-
tients with JIA compared with the plasma MPO concen-
trations in control subjects (115.2 [95 % CI, 97.4–136.3]
vs. 57.6 [95 % CI, 47.1–70.3] ng/ml; p < 0.0001).
Mean IMT values and IMT height specific SDS were
higher in the patients with JIA than in the control sub-
jects (0.46 ± 0.04 vs. 0.42 ± 0.04 mm, p < 0.0003; 1.694 ±
0.858 vs. 0.744 ± 0.852, p = 0.0002). We did not find sta-
tistically significant differences between the groups with
regard to carotid-femoral pulse wave velocity (cfPWV)
or AIx@75 (Table 1).
Serum ADMA and adiponectin levels, as well as the
mean IMT, cfPWV and AIx@75, did not differ signifi-
cantly between the JIA subtypes (data not shown).
There was a significant negative correlation between
serum adiponectin level and AIx@75 in patients with
JIA (r = −0.38; p < 0.05) (Fig. 1). No other statistically sig-
nificant correlations were found.
In multiple regression analysis, AIx@75 was independ-
ently determined by age, MAP and adiponectin levels in
patients with JIA, accounting for 29 % of its variability
(R2(adj) = 0.29; p < 0.01) (Table 2).
Discussion
We have demonstrated that, already at the time of
JIA diagnosis, there are atherosclerosis-related
changes in the arterial wall, supporting the detrimen-
tal effect of systemic inflammation on the cardiovas-
cular system. The present study is the first clinical
analysis of the relationship between adiponectin and
arterial stiffness in patients with JIA. We have shown
Table 1 Clinical and laboratory data and arterial functional-structural properties in children with juvenile idiopathic arthritis and
controls, adjusted by sex
Parameters JIA group (n = 39) Control group (n = 27) p value
Age (yr) 13.0 ± 3.11 13.5 ± 3.08 0.5687
Body mass index (kg/m2) 21.2 ± 4.09 20.2 ± 4.04 0.3364
Peripheral systolic blood pressure (mmHg) 112.2 ± 8.7 108.9 ± 8.6 0.1375
Peripheral diastolic blood pressure (mmHg) 57.6 ± 5.01 57.1 ± 4.96 0.7360
Mean arterial blood pressure (mmHg) 74.0 ± 5.82 73.3 ± 5.77 0.6549
Central systolic blood pressure (mmHg) 92.0 ± 7.5 90.17 ± 7.4 0.3748
Central diastolic blood pressure (mmHg) 58.5 ± 5.07 58.4 ± 5.04 0.9249
Cholesterol (mmol/L)a 4.1 (3.8–4.3) 4.1 (3.8–4.4) 0.8150
LDL cholesterol (mmol/L)a 2.24 (2.06–2.43) 2.36 (2.13–2.60) 0.4324
HDL cholesterol (mmol/L) 1.50 ± 0.40 1.71 ± 0.40 0.0415
Triglycerides (mmol/L)a 0.87 (0.75–1.02) 0.70 (0.59–0.84) 0.0688
ADMA (μmol/L) 0.622 ± 0.175 0.679 ± 0.173 0.2040
MPO (ng/ml)a 115.2 (97.4–136.3) 57.6 (47.1–70.3) <0.0001
Adiponectin (ng/ml)a 8596.7 (7296.3–10,128.9) 9123.1 (7506.6–11,087.7) 0.6519
Mean IMT (mm) 0.46 ± 0.04 0.42 ± 0.04 0.0003
IMT SDS, height-specificb 1.694 ± 0.858 0.744 ± 0.852 0.0002
cfPWV (m/s)a 4.92 (4.71–5.14) 5.18 (4.90–5.47) 0.1579
AIx@75 (%) 0.642 ± 11.258 −2.042 ± 11.179 0.3811
ADMA Asymmetric dimethylarginine, AIx@75 augmentation index values adjusted to a heart rate of 75 beats/min, cfPWV carotid-femoral pulse wave velocity, HDL
high-density lipoprotein cholesterol, JIA juvenile idiopathic arthritis, LDL low-density lipoprotein cholesterol, MPO myeloperoxidase, SDS standard deviation score
Values are mean ± standard deviation unless otherwise indicated
aData were log-transformed before statistical analysis and are presented as geometric mean (95 % confidence interval)
bData for34 patents with JIA and 23 control were analysed as reference values and are available for the height of 140 cm and taller [25]
Fig. 1 Correlation between serum adiponectin (ADIPO) concentration and augmentation index values adjusted to a heart rate of 75 beats/min
(AIx@75) in patients with juvenile idiopathic arthritis (r = −0.38; p < 0.05)
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Table 2 Multiple regression model for patients with juvenile
idiopathic arthritis with augmentation index values adjusted to
a heart rate of 75 beats/min as the dependent variable
Parameter Regression coefficient Standard deviation p value
Age −1.71 0.62 0.009
MAP 0.73 0.27 0.01
Adiponectin −0.001 0.0004 0.03
MAP mean arterial pressure
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in a cohort of patients with JIA. This finding suggests
that adiponectin might influence arterial stiffening in
the early stages of the disease. In addition, we dem-
onstrated that serum MPO is significantly higher in
patients with JIA. Thus, MPO may be a sensitive
marker of systemic inflammation and oxidative stress
in patients with newly diagnosed JIA.
To date, IMT in patients with JIA has been reported
in a few studies, with controversial results. Breda et al.
reported increased mean IMT in these patients [19],
whereas Vlahos et al. did not find a statistically signifi-
cant difference in IMT between their JIA and control
groups [18]. Comparing mean IMT between JIA sub-
types, Vlahos et al. found that a systemic arthritis (high
inflammatory activity) group had a thicker intima-media
layer compared with the control group and the oligoarti-
cular group [18]. Both of these studies were done in
patients with previously diagnosed JIA [18, 19]. By con-
trast, our study was conducted with patients at the very
early stage of the disease, and we demonstrated that
IMT is increased in patients with JIA already in the early
phase. We did not find a significant difference in IMT
thickness between the oligo- and polyarticular subtypes.
So far, only Breda et al. have investigated the changes in
IMT longitudinally in patients with JIA. They found that
after a 12-month treatment period, the mean IMT im-
proved; that is, was less than at the start of the study
[19]. This points out the importance of early, adequate,
aggressive treatment of JIA to controlling the possibility
of future cardiovascular events. Future investigations are
needed to verify this point.
Several studies have shown that increased MPO con-
centration is associated with an increased risk of CVD
[27, 28]. Also, studies have shown higher serum and
plasma concentrations in patients with rheumatologic
diseases [9, 29]. In our study, we found higher serum
levels of MPO in patients with JIA already at an early
stage of the disease. Thus, MPO may be a good marker
of the level of inflammation, even when the classical in-
flammation markers are at normal levels.
ADMA acts as a natural inhibitor of nitric oxide syn-
thase by reducing nitric oxide production. Higher levels
of ADMA give rise to endothelial dysfunction and arter-
ial stiffening [30]. The key enzyme in degradation ofADMA is dimethylarginine dimethylaminohydrolase,
and its activity is downregulated by tumour necrosis fac-
tor α and has a known role in the pathogenesis of RA
and JIA [31]. Higher levels of ADMA and its correlation
to oxidative stress markers have been shown in patients
with RA [7]. In children with other chronic diseases,
such as chronic kidney disease or type 1 diabetes melli-
tus, elevated serum ADMA concentrations have been
found [21, 32]. However, all these children already had
their disease for many years. To our knowledge, the level
of ADMA has not been investigated to date in patients
with JIA. In our study, we did not find a significant
difference in serum ADMA levels at the disease start be-
tween our patient and control groups.
Adiponectin has well-known anti-inflammatory prop-
erties. To the contrary, there are studies suggesting that
hypoadiponectemia might play an important role in
CVDs (e.g., hypertension) [33]. In patients with RA, adi-
ponectin levels are higher than in patients with non-
inflammatory conditions (e.g., osteoarthrosis), which is
suggestive of a proinflammatory effect [8]. Alternatively,
increased adiponectin might represent a compensatory
response limiting further vascular injury [34]. To our
knowledge, adiponectin levels have not been investigated
in patients with JIA. In our study, we did not find statis-
tically significant differences in levels of adiponectin
between patients and controls, but adiponectin was in-
versely independently correlated with AIx@75 in pa-
tients with JIA, indicating that lower levels of
adiponectin might be related to arterial stiffening already
at an early stage of JIA.
In our study, there was no significant difference in
cfPWV between the patients and the control subjects.
These findings could be due to the fact that we studied
newly diagnosed patients with JIA, whereas aortic
stiffening may occur at later stages of the disease.
Consistent with this hypothesis, a recent study has
shown that patients with JIA with long-term active
disease have increased aortic stiffness compared with
control subjects [35].
The limitations of our study are the use of a histor-
ical control group, the gender difference and the ab-
sence of patients from all the JIA subtypes (although
the two subgroups presented are the most frequent
ones in every study group of patients with JIA), which
limits extrapolation of the risk of vascular dysfunction
to all patients with JIA. At the same time, we present
a detailed, complex overview of different markers of
inflammation, oxidative stress and arterial structural-
functional properties, which describes the stage of de-
velopment of subclinical atherosclerosis in these pa-
tients. Another limitation of our study is the use of
generalized transfer function, which has been vali-
dated only in adults.
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Our study shows that patients with JIA have signs of
alterations in arterial structural properties already at
the time of diagnosis of the disease. Independent in-
verse association between the atherosclerosis-related
biomarker adiponectin and arterial stiffness suggests
that hypoadiponectemia may influence vascular func-
tion in these patients. Further investigations are
needed to clarify the risk of vascular dysfunction dur-
ing the disease course and to identify children who
are at increased risk of early development of athero-
sclerosis in adulthood.
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